

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:
C07D 205/08
A1
(11) International Publication Number: WO 00/34240
(43) International Publication Date: 15 June 2000 (15.06.00)

(21) International Application Number:

PCT/US99/27914

(22) International Filing Date:

6 December 1999 (06.12.99)

(30) Priority Data:

09/206,931

7 December 1998 (07.12.98) US

- (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).
- (72) Inventors: THIRUVENGADAM, Tiruvettipuram, K.; 17 Village Road, Kendall Park, NJ 08824 (US). FU, Xiaoyong; 18 Augusta Avenue, Edison, NJ 08820 (US). TANN, Chou-Hong; 30 Pinewood Crescent, Berkeley Heights, NJ 07922 (US). McALLISTER, Timothy, L.; Apartment 3L, 1 Primrose Lane, Fords, NJ 08863 (US). CHIU, John, S.; 12 Ferndale Drive, Parsippany, NJ 07054 (US). COLON, Cesar; 849 Apgar Terrace, Rahway, NJ 07065 (US).
- (74) Agents: MAGATTI, Anita, W. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, IP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PROCESS FOR THE SYNTHESIS OF AZETIDINONES

(57) Abstract

This invention provides a process for preparing the hypocholesterolemic compound (I) comprising: (a) reacting p-fluorobenzoylbutyric acid with pivaloyl chloride and acylating the product with a chiral auxiliary to obtain a ketone of formula (IV); (b) reducing the ketone of formula (IV) in the presence of a chiral catalyst to an alcohol; (c) reacting the chiral alcohol of step (b), an imine and a silyl protecting agent, then condensing the protected compounds to obtain a β -(substituted-amino)amide of formula (VII); (d) cyclizing the β -(substituted-amino)amide of formula (VII) with a silylating agent and a fluoride ion catalyst to obtain a protected lactam of formula (VIII); and removing the protecting groups. The intermediates of formulas (VIII and VIII) are also claimed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

٨L	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Amenia	FI	Pinland	LT	Litheania	SK	Slovakia
AT	Austria	FR	Prance	w	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvis	SZ	Swaziland
AZ	Azerbaijaa	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Horzegovine	GE.	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgina	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
B F	Burkina Puso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobeso
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brezil	IL	Israel	MR	Mauritania	UG	Uganda.
BY	Belarus	18	Iceland	MW	Malawi	US	United States of Americ
CA	Canada	IT	kaly	MX	Mexico	UZ.	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KOR	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwa
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cubs	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	u	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PROCESS FOR THE SYNTHESIS OF AZETIDINONES

Background

10

This invention relates to an enantioselective process for producing hydroxy-alkyl substituted azetidinones useful as hypocholesterolemic agents, in particular for preparing 1-(4-fluorophenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone, claimed in US 5,767,115.

15

Processes for preparing the corresponding azetidinone without the 3-hydroxy substitutent are claimed in US 5,728,827 and US 5,561,227. Other processes for preparing 1-(4-fluorophenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)-propyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone are disclosed in US 5,631,365 and US 5,739,321.

20

Summary of the Invention

This invention provides an improved simple, high-yielding process using neutral conditions for producing the hypocholesterolemic azetidinone having the formula I

25

30

comprising:

(a) reacting p-fluorobenzoylbutyric acid of formula II with pivaloyl chloride and acylating the product with a chiral auxiliary of formula III to obtain a ketone of formula IV:

10

wherein X is -O-, -S- or -N(C_1 - C_6 alkyl); Y is =O or =S; and R¹ is C_1 - C_6 alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, C_1 - C_6 alkoxycarbonyl or benzyl, wherein the substituents on phenyl and naphthyl are 1-3 substituents selected from the group consisting of C_1 - C_6 alkyl, phenyl and benzyl;

(b) reducing the ketone of formula IV in the presence of a chiral catalyst to an alcohol of formula V:

(c) reacting the chiral alcohol of formula V, an imine of formula VI and a silyl protecting agent, then condensing the silyl-protected compounds to obtain a β-(substituted-amino)amide of formula VII, wherein Prot is a silyl protecting group:

- (d) cyclizing the β -(substituted-amino)amide of formula VII with
- 15 (i) a silylating agent and a fluoride ion catalyst cyclizing agent;
 - (ii) a silylating agent and a quaternary ammonium salt of a chiral auxiliary of formula III; or
 - (iii) a strong non-nucleophlic base;

to obtain the compound of formula VIII:

20

(e) removing the silyl protecting groups.

Also claimed are the process comprising steps (c), (d) and (e); the process of steps (d) and (e); the process of step (c); and the process of step (d), particularly the cyclization described in step (d)(i).

In still another aspect, the intermediates of formula VII and VIII are claimed.

The process described above is directed to the preparation of the 1-(4-fluorophenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone enantiomer, but it will be recognized that by substitution of the appropriate starting materials, other enantiomers can be

prepared.

Detailed Description

10 The process of this invention is a high throughput process which provides the desired azetidinone in high overall yield in a short time cycle (i.e., about two weeks).

Preferred reaction conditions are shown in the following scheme:

Step (a):

`15

Step (c):

10

20

In the reaction scheme, TEA is triethylamine, DMAP is 4-dimethylamino pyridine, DIPEA is diisopropylethylamine, BSA is bistrimethylsilyl acetamide, TBAF is tetra n-butyl-ammonium fluoride, t-BuOMe is t-butyl methyl ether and Prot is a silyl protecting group as defined below.

Starting materials of formulas II and III are known in the art, and the procedure of step (a) for reacting compounds of formula II and III is known in the art: Preferably, the chiral auxiliary of formula III is exemplified by the formula:

wherein Y is =0, X is -0- and R^1 is phenyl, benzyl or C_1 - C_6 alkyl. A

15 See the example below for typical reaction conditions.

Similarly, the procedure of step (b) for reducing a ketone to a hydroxy group using a borane reducing agent such as BH₃• S(CH₃)₂ in the presence of a chiral catalyst such as (R)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo(1,2-c)(1,3,2) oxaza-borolidine is known: see U.S. 5,767,115.

15

20

25

30

35

In step (c), the chiral alcohol, V, and the imine, VI, are protected with a suitable hydroxy-protecting group, preferably a silyl protecting group such as that derived from chlorotrimethylsilane (TMSCI) or t-butyldimethyl-silyl chloride (TBDMSCI). The alcohol (1 equivalent) and imine (preferaby 1-3 equivalents) are added to an anhydrous solvent such as CH₂Cl₂, the reaction mixture is cooled to -10° to 15°C, a tertiary amine base such as DIPEA is added (preferably 2-4 equivalents), and sufficient silylating reagent to react with both the alcohol and the imine is added (e.g., 2-4 equivalents). After silylation is complete, the alcohol and imine are condensed by reacting at -20° to -35°C with at least 1 equivalent of a Lewis acid such as TiCl₄, in the presence of a tertiary amine base (preferably 1-3 equivalents) such as DIPEA for 2-4 hours. The reaction is quenched, for example by treating with an acid such as glacial acetic acid followed by aqueous tartaric acid solution; the resultant product is extracted and crystallized using conventional procedures.

Silylation in step (d) is effected by reacting the compound of formula VII with a silyl-enol ether silylating agent such as bistrimethylsilyl acetamide (BSA), N-methyl-O-trimethylsilyl acetamide or iso-propenyloxy trimethylsilane, preferably BSA, in a suitable inert organic solvent at -20°C to 110°C, preferably at about 0°C to 25°C. The reaction is preferably carried out in a dry, inert atmosphere, e.g., the solvent is dried, typically with molecular sieves, and the reaction is carried out under nitrogen.

The order of addition of the components of this process in Step (d) is not critical to the preparation of the azetidinone product. For example, the β -(substituted-amino)amide can first be reacted with the silylating agent and then reacted with the cyclizing agent, or the compound of formula VII can be added to a mixture of the silylating agent and the cyclizing agent. When the silylation and cyclization are done sequentially, i.e., the silylating agent is reacted with the starting material first, the silylation reaction can be allowed to continue for up to about two hours, but preferably the cyclization step is carried out immediately after silylation, or the silylating agent and the cyclizing agent are added simultaneously.

The source of the fluoride ion used to catalyze the intra-molecular cyclization of the compound of formula VII is typically a quaternary alkyl-, aryl-alkyl- or arylalkyl-alkylammonium fluoride salt or a hydrate thereof, or a mixture thereof, or is an alkali metal fluoride salt or a hydrate thereof, such as cesium fluoride or potassium fluoride. Examples of arylalkyl-

15

20

25

30

alkylammonium groups are benzyltriethyl-ammonium and benzyltrimethylammonium; examples of arylalkyl-ammonium are phenyltriethylammonium and phenyltrimethyl-ammonium; typical alkylammonium groups contain alkyl groups of 1-6 carbon atoms, e.g., tetra n-butyl-ammonium. When a hydrated quaternary ammonium fluoride salt is used, the reagent is added in a catalytic amount, i.e., about 0.1 to about 20 mole percent, preferably about 0.5 to 5 mole percent, and when an anhydrous quaternary ammonium fluoride salt is used, it can be added in a catalytic up to a stoichiometric amount. When an alkali metal fluoride salt is used, it is added in catalytic amount up to a stoichiometric amount compared to the starting β-amino compound, depending on the solubility of the reagent in the solvent used (higher solubility requires less reagent). If added to the reaction mixture after the silvlation agent, the fluoride reagent is added directly to the reaction mixture resulting from silylation, and is reacted at about 0°C to 110°C, preferably about 0°C to 50°C, for about 0.5 to about 6 hours, preferably about 2 hours. When the silylation reagent and the fluoride reagent are added simultaneously, the reaction is conducted under similar conditions. A preferred fluoride ion catalyst cyclizing agent is tetrabutylammonium fluoride trihydrate.

Alternatively, the cyclization of step (d) can be effected by the addition of a monovalent quaternary ammonium salt of the chiral auxiliary of formula III used in step (a), i.e., a compound of the formula

$$Z^+ \gamma X \quad \text{or} \quad HN X$$

wherein X, Yand R¹ are as defined above and Z is a quaternary ammonium cation selected from the group consisting of arylalkyl-alkylammonium, arylalkylammonium and tetraalkylammonium, or a mixture thereof, and alkali metals. Examples of arylalkyl-alkylammonium are benzyltriethylammonium and benzyl-trimethylammonium; examples of aryl-alkylammonium are phenyltriethylammonium and phenyltrimethyl-ammonium; typical tetraalkylammonium groups contain alkyl groups of 1-6 carbon atoms, e.g., tetra n-butylammonium; and typical alkali metals are sodium, potassium, cesium and lithium. Other chiral or non-chiral auxiliaries can also be used to cyclize the β -(substituted-amino)amide of formula VII, for example compounds of the formulas

15

20

25

30

$$Z^+ \stackrel{\mathsf{N}}{\underset{\mathsf{R}^1}{\bigvee}} \stackrel{\mathsf{X}}{\underset{\mathsf{R}^2}{\bigvee}} \stackrel{\mathsf{Or}}{\underset{\mathsf{R}^1}{\bigvee}} \stackrel{\mathsf{H}}{\underset{\mathsf{R}^2}{\bigvee}} \stackrel{\mathsf{Y}^{-+}\mathsf{Z}}{\underset{\mathsf{R}^2}{\bigvee}}$$

wherein X, Y, Z and R¹ are as defined above and R² is defined as for R¹ can also be used. The the β -(substituted-amino)amide of formula VII is treated with a silylating agent as described above, with the salt of the chiral (or non-chiral) auxiliary being added either simultaneously or sequentially in a catalytic or stoichiometric amount compared to the β -amino compound under conditions similar to the reaction with fluoride ion.

A third method for cyclizing the β -(substituted-amino)amide of formula VII comprises using a strong non-nucleophilic base. A strong non-nucleophilic base is defined herein as a non-aqueous base which does not act as a nucleopile by virtue of its steric bulk, e.g., sodium bistrimethylsilylamide or lithium diisopropylamide. The base is reacted with the β -amino compound in an inert organic solvent such as CH_2Cl_2 at a temperature of about -100°C to 10 °C.

Removal of the protecting groups after cyclization is carried out using conventional methods, for example by treatment with a dilute acid such as sulfuric acid in a solvent such as an alcohol, e.g., isopropanol.

Intermediates IV and VII can be isolated during the reaction process, or the reaction can proceed to formation of the compound of formula I before the product is isolated.

The azetidinone resulting from the cyclization can be purified by appropriate standard procedures such as crystallization or column chromatography.

The term "suitable inert organic solvent" as used above means any organic solvent or combination of solvents that is unreactive in the reaction being conducted and is a solvent for the reactants. Typical suitable solvents are halogenated compounds such as CH₂Cl₂; heterocyclic compounds such as tetrahydrofuran (THF); DMSO; dimethylformamide (DMF); acetonitrile; carbocyclic aromatics such as toluene; and t-BuOMe. Preferred are t-BuOMe, CH₂Cl₂, toluene and THF.

Those skilled in the art will recognize that for cyclization of step (d) to proceed as desired, the -OH substituents present in the intermediates of formulas V and VI used in step (c) must be protected prior to cyclization, hence the treatment in step (c) with a hydroxy-protecting group. A key

10

15

20

25

feature of this process is the surprising stability of the silyl protecting groups on the carbinol and phenol moieties in both step (c) and step (d). In step (c), after the reaction of intermediates V and VI, the reaction is quenched with acid, preferably acetic acid and aqueous tartaric acid: the resulting solution has a pH <1. Under these conditions, one would not predict that the disilylated compound of formula VII (containing a silylated phenolic group) would be stable, but surprisingly the compound is stable and can be isolated for use in the next step of the process. Also, in step (d) of the process of the invention, out of the three silylated groups (i.e., the two hydroxy groups silylated in step (c) and the -NH- group silylated in the first part of step (d)), the -N-Si- group is selectively desilylated, allowing the intramolecular cyclization to proceed efficiently. This was unpredictable, especially in view of the presence of a silylated phenol group.

The following example illustrates the process of this invention.

<u>Step (a):</u>

Equip a 3-necked 500 mL round bottom flask with a thermometer, an addition funnel and a nitrogen inlet. Add p-fluoro-benzoylbutyric acid (20 g, 95.15 mmol), CH₂Cl₂ (100 mL) and TEA (23 mL, 165 mmol) and agitate the mixture at room temperature for 5 min. Add trimethylacetyl chloride (11.3 mL, 91.75 mmol) slowly over a period of 30 min. Check for complete formation of mixed anhydride by NMR.

Add the compound of formula III (10 g, 61.3 mmol), DMAP (1.6 g, 13 mmol) and dry DMF (10 mL) and heat the mixture at reflux for about 7 h or until the reaction is complete (<3% compound III) by NMR. Cool to room temperature, transfer the batch to a flask containing 2N $\rm H_2SO_4$ (80 mL) slowly with agitation and continue agitation for about 30 min. Separate the layers and wash the organic layer with 5% NaHCO₃ (80 mL)

Concentrate the organic layer and crystallize the product from isopropyl alcohol (100 mL), filter and dry. Yield: 20 g (92% molar); mp: 92-94°C.

Step (b):

5

10

15

20

25

Equip a 3-necked 250 mL round bottom flask with a thermometer, an addition funnel and a nitrogen inlet. Add dry CH₂Cl₂ (20 mL) and neat borane dimethyl sulfide (2.82 mL, 28.2 mmol) and cool the mixture to -5° to 0°C. Add a previously prepared toluene solution of (R)-tetrahydro-1methyl-3,3-diphenyl-1H,3H-pyrrolo(1,2-c)(1,3,2) oxaza-borolidine (1.4 mL, 1.4 mmol, 5 mole %) to the mixture and stir for 15 min. at < 0°C. Add a solution of compound IV(10 g, 28.1 mmol) in CH₂Cl₂ (30 mL) slowly over a period of 3-4 h and maintain the reaction temperature between -5° to 0°C. Continue stirring for 1 to 2 h or until the reaction complete (<0.1% compound IV) by NMR. Quench the reaction by slowly adding CH₃OH (4 mL) while maintaining the temperature <0°C. Add 5% hydrogen peroxide (20 mL) followed by 4N H₂SO₄ (1.5 mL). Agitate the mixture for 15 min., separate the organic layer and wash with 2N H_2SO_4 (20 mL), 5% Na₂SO₃ (50 mL) and 10% NaCl (50 mL). Concentrate the organic layer to a low volume until water content is <0.05%. The product is used directly in the next step. Solution yield: >95%; de: 98%. Step (c):

Equip a 3-necked 500 mL round bottom flask with a thermometer, an addition funnel and a nitrogen inlet. Add the CH₂Cl₂ solution of compound V (10 g equivalent of compound IV, 28.1 mmol) from step (b) and compound VI (12.05 g) and adjust the total volume of the reaction

10

15

25

mixture to 150 mL with dry CH₂Cl₂. Cool the mixture to -10°C and add slowly DIPEA (25.7 mL, 147.5 mmol) and maintain the temperature at < -5°C. Add TMSCI (13.5 mL, 92.3 mmol) over a period of 30 min. while maintaining the reaction temperature <-5°C. Agitate the reaction for 1 h or until the silylation is judged complete by NMR. Lower the reaction temperature to -25 to -30°C. Add TiCl₄ (3.4 mL, 30.8 mmol) slowly and maintain the temperature <-25°C. Agitate the reaction for 3 h at <-25°C and check the reaction completion by NMR. Add glacial acetic acid (8 mL) slowly to the reaction mixture while maintaining the reaction temperature between -25 and -30°C. Pour the reaction mixture into 7% aqueous tartaric acid solution (140 mL) at 0°C, agitate for 1-2 h, and allow the temperature to gradually rise to room temperature. Add 20% aqueous NaHSO3 solution (50 mL) and continue agitation for another 2 h. Separate the organic layer and wash with water (120 mL). Concentrate the organic layer to a low volume and add bistrimethylsilyl acetamide (8.4 mL) and heat the mixture to reflux for 30 min. Concentrate the mixture to remove CH₂Cl₂ and crystallize the product from an ethyl acetate and heptane mixture, filter, wash and dry to give 13 g (65% molar yield from compound IV) of compound VII.

20 Step (d):

Equip a 3-necked 500 mL round bottom flask with a thermometer, an addition funnel and a nitrogen inlet. Add compound VII (50 g, 69.7 mmol), tetrabutylammonium fluoride trihydrate (0.1 g, 0.32 mmol), bistrimethyl acetamide (30 mL) and t-butylmethyl ether (500 mL). Stir the mixture at room temperature for 2 h or until the reaction is judged complete by NMR. Add glacial acetic acid (2.5 mL) and concentrate the reaction mixture to an oil under vacuum.

Step (e):

20

25

30

Add a premixed solution of isopropyl alcohol (250 mL) and 2N H_2SO_4 (25 mL) to the product of step (d) and agitate the mixture at room temperature for 1 h. Crystallize compound I from aqueous isopropyl alcohol. Filter the product and wash with dilute aqueous isopropyl alcohol followed by water until the pH of wash is <5. Dry the product at 60°C in a draft oven or under vacuum to give 26.14 g (91.5% molar yield) of compound I.

Starting materials for the claimed process are made by the following typical procedures.

10 Preparation of 4-(4-fluorobenzoyl)butyric acid:

Charge 250 g of anhydrous AlCl₃ (1.87 moles) to a 2 L 3-neck round bottom flask, add 300 mL fluorobenzene (307.5 g; 3.2 moles) and cool the mixture in an ice bath to 5°C. Add a hazy suspension of 100 g glutaric anhydride (0.86 mole) in 400 mL fluorobenzene (4.3 moles) through an addition funnel over a period of 45 min., and maintain the temperature below 12°C. Warm the reaction mixture to ambient temperature gradually and agitate at r.t. for about 90 min.; check for completion by NMR. Cool the reaction mixture to 0 to 5°C, then add a cold aqueous solution (700 mL) of 1N HCl carefully to the mixture to destroy any unreacted AICl3, keeping the temperature of the mixture below 20°C during the early part of the acid addition, and below 40°C for the rest of the time. Pour the entire mixture into a 2 L 1:1 mixture of water and ice (v/w) to precipitate out crude products, filter the white suspension and wash well with water. Add the white residue to 3 L of aqueous saturated solution (~5%) of NaHCO₃, heat the basic mixture on a steam bath for one hour and filter the batch while hot through a thin pad of celite. Cool the filtrate to r.t., add about 320 mL of concentrated HCl dropwise into the filtrate to pH 1 to crystallize out products, and agitate the white suspension in an ice bath for 30 min. Filter the batch, wash the wet cake with ice cold water and dry in a vacuum oven at 50°C for 16 h to obtain 143.2 g of 4-(4-fluorobenzoyl)-butyric acid; m.p. 141 to 142°C, isolated yield: 79.3%.

Preparation of Imine:

10

Equip a three necked 1L flask with a mechanical stirrer, thermometer and an addition funnel. Add 480 mL of isopropanol, 144 g (1.18 moles) of p-hydroxybenzaldehyde (endothermic) and agitate the mixture while heating to a temperature of 50°C. Agitate the mixture at 50°C for 15 min (making sure all the material is in solution), then add 114 mL (1.2 moles) of p-fluoroaniline slowly via the addition funnel (exothermic reaction). After the addition is complete, agitate the thick slurry for 1hr at 50°C, cool to r.t. and agitate for 30 min. Filter the product, wash the cake with 150 mL of isopropanol, dry the wet cake in a draft oven at 50°C for 24 h or until dry to yield 222 g of the imine (88%); mp: 180-182°C

We claim:

1. A process for preparing a compound represented by the formula

5 comprising:

15

(a) reacting p-fluorobenzoylbutyric acid of formula II with pivaloyl chloride and acylating the product with a chiral auxiliary of formula III to obtain a ketone of formula IV:

- wherein X is -O-, -S- or -N(C₁-C₆ alkyl); Y is =O or =S; and R¹ is C₁-C₆ alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, C₁-C₆ alkoxycarbonyl or benzyl, wherein the substituents on phenyl and naphthyl are 1-3 substituents selected from the group consisting of C₁-C₆ alkyl, phenyl and benzyl;
 - (b) reducing the ketone of formula IV in the presence of a chiral catalyst to an alcohol of formula V:

$$F \xrightarrow{N} X \xrightarrow{N} Y \xrightarrow{N} X$$

(c) reacting the chiral alcohol of formula V, an imine of formula VI and a sityl protecting agent, then condensing the silyl-protected
 compounds to obtain a β-(substituted-amino)amide of formula VII, wherein Prot is a silyl protecting group:

10

15

- (d) cyclizing the β -(substituted-amino)amide of formula VII with
- (i) a silylating agent and a fluoride ion catalyst cyclizing agent;
- (ii) a silylating agent and a quaternary ammonium salt of a chiral auxiliary of formula III; or
- (iii) a strong non-nucleophlic base; to obtain the compound of formula VIII:

- (e) removing the silyl protecting groups.
- 2. The process of claim 1 wherein in step (a), the chiral auxiliary is (4S)-4-phenyl-2-oxazolidinone; in step (b) the chiral catalyst is (R)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo(1,2-c)(1,3,2) oxaza-borolidine; in step (c) the silyl protecting agent is chlorotrimethylsilane, the Lewis acid is TiCl₄ and the tertiary amine is diisopropylethylamine; and in step (d) the silylating agent is bistrimethylsilyl acetamide and the fluoride ion catalyst cyclizing agent is tetrabutylammonium fluoride trihydrate.
- 3. A process for preparing a compound represented by the formula

20

comprising:

reacting a chiral alcohol of formula V, an imine of formula VI and a silyl protecting agent, then condensing the silyl-protected compounds to obtain a β -(substituted-amino)amid of formula VII, wherein X is -O-, -S- or

-N(C₁-C₆ alkyl); Y is =O or =S; and R¹ is C₁-C₆ alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, C₁-C₆ alkoxycarbonyl or benzyl, wherein the substituents on phenyl and naphthyl are 1-3 substituents selected from the group consisting of C₁-C₆ alkyl, phenyl and benzyl; and wherein Prot is a silyl protecting group:

cyclizing the β -(substituted-amino)amide of formula VII with a silylating agent and a fluoride ion catalyst cyclizing agent to obtain the compound of formula VIII:

10

15

5

removing the silyl protecting groups.

- 4. A process of claim 3 wherein the the silyl protecting agent is chlorotrimethylsilane; the condensation is effected with a Lewis acid in the presence of a tertiary amine; and the silylating agent is bistrimethylsilyl acetamide and the fluoride ion catalyst cyclizing agent is tetrabutylammonium fluoride trihydrate.
- 5. A process for preparing a compound represented by the formula

20

comprising cyclizing a β -(substituted-amino)amide of formula VII,

wherein X is -O-, -S- or -N(C_1 - C_6 alkyl); Y is =O or =S; and R^1 is C_1 - C_6 alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, C_1 - C_6 alkoxycarbonyl or benzyl, wherein the substituents on phenyl and naphthyl are 1-3 substituents selected from the group consisting of C_1 - C_6 alkyl, phenyl and benzyl; and wherein Prot is a silyl protecting group, with a silylating agent and a fluoride ion catalyst cyclizing agent to obtain the compound of formula VIII:


10

- (e) removing the silyl protecting groups.
- 6. A process of claim 5 wherein the silylating agent is bistrimethylsilyl acetamide and the fluoride ion catalyst cyclizing agent is tetrabutylammonium fluoride trihydrate.

15

20

7. A process for preparing a β-(substituted-amino)amide of the formula



wherein X is -O-, -S- or -N(C_1 - C_6 alkyl); Y is =O or =S; and R^1 is C_1 - C_6 alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, C_1 - C_6 alkoxycarbonyl or benzyl, wherein the substituents on phenyl and naphthyl are 1-3 substituents selected from the group consisting of C_1 - C_6 alkyl,

phenyl and benzyl; and wherein Prot is as defined above, with a silylating agent and a fluoride ion catalyst cyclizing agent.

- 10. A process of claim 9 wherein the silylating agent is bistrimethylsilyl
 acetamide and the fluoride ion catalyst cyclizing agent is tetrabutylammonium fluoride trihydrate.
 - 11. A compound of the formula

- wherein Prot is a silyl protecting group.
 - 12. A compound of the formula

wherein Prot is a silyl protecting group.

PCT/US 99/27914

ÎPC 7	CO7D205/08			
According to	to International Patent Classification (IPC) or to both national desails	estion and IPC		
B. FIELDS	SEARCHED			
IPC 7		,		
	tion searched other than minimum documentation to the extent that	_		
-	tets base consulted during the International search (name of data b	eee and, where practical, search terms used		
	ENTS CONSIDERED TO BE RELEVANT			
Category *	Challon of document, with indication, where appropriate, of the n	elevent passages	Relevent to claim No.	
Y	WO 97 16424 A (SCHERING CORPORAT 9 May 1997 (1997—05—09) the whole document	ION)	1	
Υ	US 5 767 115 A (STUART B. ROSENB AL.) 16 June 1998 (1998-06-16) cited in the application the whole document	LUN ET	1	
Υ	US 5 739 321 A (GUANG-ZHONG WU E 14 April 1998 (1998-04-14) cited in the application the whole document	T AL.)	1	
		-/ 		
ست ا	her documents are listed in the confinuation of box C.	Patent family members are Ested	In armox.	
"A" document of the control of the c	ant which may frow doubts on palosity claim(a) or to clied to establish the publication date of another in or other special reason (as appolled) ant referring to an one disclosure, use, establish or means ant published prior to the international filing date but him the priority date claimed	The later document published after the interestional filing date or patelly date and not in conflict with the application but clied to understand the principle or theory underlying the invention. The document of perfousier relevance; the claimed invention commot be considered novel or commot be considered to involve an inventive step when the document is taken atone. The document of perfousier relevance; the claimed invention commot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person sidled in the set. The document member of the same patent tendly.		
	April 2000	Date of mailing of the international sec	erch report	
Name and r	melling address of the IBA Buropean Patent Office, P.B. 5818 Patentiaen 2 ML — 2280 HV Rijheeljt Tel. (+81-70) 340-2040, Tx. 31 651 epo ril, Fac: (+31-70) 340-3016	Authorized officer Kyrriakakou, G		

Form PCT/REARITO (second sheet) (July 1992)

PCT/US 99/27914

C.(Continu	ntion) DOCUMENT'S CONNIDERED TO BE RELEVANT	101/03 93/2/914
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to dain No.
Y	US 5 728 827 A (TIRUYETTIPURAM KANNAPAN THIRUYENGADAM ET AL.) 17 March 1998 (1998-03-17) cited in the application the whole document	I
Y	US 5 561 227 A (TIRUVETTIPURAM K. THIRUVENGADAM ET AL.) 1 October 1996 (1996—10—01) cited in the application the whole document	1
ſ	US 5 631 365 A (STUART B. ROSENBLUM ET AL.) 20 May 1997 (1997-05-20) cited in the application the whole document	1
		υ. *
	10 (confination of second abset) (July 1902)	

information on patent family members

PCT/US 99/27914

Patent document cited in search report	t ·	Publication date	- 1	Patent family . member(s)	Publication date
WO 9716424		00-05 1007	411		<u> </u>
MO 3/10424	A	09-05-1997	AU Us	7472896 A	22-05-199
			02	5856473 A	05-01-199
US 5767115	A	16-06-1998	US	5631365 A	20-05-199
			US	5846966 A	08-12-199
			AT	180249 T	15-06-199
			AU	681445 B	28-08-199
			AU	7795294 A	10-04-199
			CN CZ	1131416 A 9600839 A	18-09-199 14-08-199
			DE	69418613 D	24-06-199
			DE	69418613 T	3009199
			EP	0720599 A	10-07-199
			ES	2132432 T	16-08-199
			FI	961300 A	21-03-199
			GR	3030312 T	30-09-199
			HU	73852 A	30-09-199
			JP	2803908 B	24-09-199 22-10-100
			JP Kr	8509989 T 186853 B	22-10-199 01-05-199
			NO	961133 A	20-03-199
			NZ	274041 A	19-12-199
			PL	313589 A	08-07-199
			SG	46208 A	20-02-199
			SK	35596 A	05-02-199
			WO	9508532 A	30-03-199
·-·.			ZA	9407086 A	14-03-199
US 5739321	A	14-04-1998	AU	3299497 A	05-01-199
			EP	0906278 A	07-04-199
			JP	11511754 T	12-10-199
			WO	9745406 A	04-12-199
US 5728827	· A	17-03-1998	AU	681419 B	28-08-199
			AU	721 4694 A	06-02-199
			CA CN	2166784 A 1126989 A	19-01-199 17-07-199
			CZ	9600076 A	17-04-199
			EP	0707567 A	24-04-199
			FI	960095 A	09-01-199
			HU	73237 A	29-07-199
			JP	2840452 B	24-12-199
			JP	8507085 T	30-07-199
			KR	176001 B	20-03-199
			MX	9405152 A	31-01-199
			NO NZ	960083 A 268798 A	04-03-199 29-01-199
			PL	312502 A	29-04-199
			SK	3796 A	05-02-199
			WO	9501961 A	19-01-199
UC FF61007	Α	01-10-1996	116	E206017 A	26-04-199
II	Α	01-10-1220	US Au	5306817 A 658441 B	26-04-199 13-04-199
US 5561227			CZ	9400142 A	13-07-199
N2 2201551			~~	JAAATAE V	
US 550122/				69222532 D	(10-11-1Ai
JS 550122/			DE De	69222532 D 69222532 T	06-11-199 26-02-199
US 556122/			DE	69222532 D 69222532 T 0596015 A	

intermetion on patent family members

PCT/US 99/27914

Patent document cited in search report	;			Patent family member(s)	Publication date	
US 5561227	A		JP	6508637 T	29-09-1994	
			NO	940221 A	21-01-1994	
			SK	7994 A	06-07-1994	
			ÜS	5688787 A	18-11-199	
			AT	158789 T	15-10-199	
			AU	2398092 A	23-02-199	
			BG	61118 B	29-11-199	
			CA	2114007 A	04-02-1993	
			CN	1069024 A	17-02-199	
			EP	0524595 A	27-01-199	
			ËS	2107548 T	01-12-199	
			HU	67341 A	28-03-199	
			. JP	2525125 B	14-08-199	
			MX	9204327 A	29-07-199	
			MZ NZ	243669 A	29-07-199	
			0A	243009 A 9878 A		
			MO	9302048 A	15-09-199 04-02-199	
			US	5688785 A		
			ZA		18-11-199	
				9205487 A	31-03-199	
US 5631365	A	20-05-1997	AT	180249 T	15-06-199	
			AU	681445 B	28-08-199	
			AU	7795294 A	10-04-199	
			CN	1131416 A	18-09-199	
			CZ	9600839 A	14-08-199	
			DE	69418613 D	24-06-199	
			DE	69418613 T	3 0- 09 - 199	
			EP	0720599 A	10-07-199	
			ES	2132432 T	16-08-199	
•			FI	961300 A	21-03-199	
			GR	3030312 T	30-09-199	
			HÜ	73852 A	30-09-199	
			JP	2803908 B	24-09-199	
			JP	8509989 T	22-10-199	
			KR	186853 B	01-05-199	
			NO	961133 A	20-03-199	
		•	NŽ	274041 A	19-12-199	
			PL	313589 A	08-07-199	
			SG	46208 A	20-02-199	
			SK	35596 A	05-02-199	
			MO	9508532 A	30-03-199	
			US	5767115 A	16-06-199	
			US	5846966 A	08-12-199	
			ZA	9407086 A	14-03-199	

